Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.36 |
| ▸ | CCR1 | P32246 | 8/20 | 0.34 |
| ▸ | CCR2 | P41597 | 8/20 | 0.34 |
| ▸ | CCR4 | P51679 | 7/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16631906 | 0.85 | CYP19A1 (0.38) | CYP19A1CCR1CCR2CCR4PTGDR2 | |
| SCHEMBL18080394 | 0.80 | MAPK1 (0.33) | MET | |
| SCHEMBL18080395 | 0.78 | NTRK1 (0.32) | — | |
| SCHEMBL18080393 | 0.77 | CYP19A1 (0.33) | CYP19A1METCYP2C19 | |
| SCHEMBL18080397 | 0.76 | PTGDR2 (0.36) | CYP19A1CCR1CCR2CCR4PTGDR2 | |
| SCHEMBL10137841 | 0.74 | SMN1; SMN2 (0.41) | METCYP2C19 | |
| SCHEMBL18080400 | 0.74 | CYP19A1 (0.50) | CYP19A1MET | |
| SCHEMBL18080372 | 0.73 | NOTUM (0.36) | MET | |
| SCHEMBL18858876 | 0.71 | MET (0.39) | METCYP2C19 | |
| SCHEMBL21637955 | 0.71 | SMN1; SMN2 (0.36) | METCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | CYP19A1 4868/4885CCR1 3027/4885CCR2 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.